By Alison Kodjak
Drug companies could be forgiven if they're confused about whether President Donald Trump thinks the government should get involved in negotiating the price of prescription drugs for Medicare patients.
"There's a reason why the pharmaceutical industry does not want Medicare negotiation to happen," Gellad told NPR. "And the obvious reason is because it will lower prices."
If Medicare, for example, said it would pay for only one of the two major Hepatitis C medications on the market today — drugs that cost upwards of $40,000 for a course of treatment — Gellad estimates the drugmakers would cut the price by at least $10,000 to win the government's business...
Continue reading...
No comments:
Post a Comment